Helicase mutant and application thereof

By modifying amino acids in the flexible region of helicase, it improves its thermal stability and sequencing performance, the problem of insufficient thermal stability of helicase in nanopore sequencing technology in high temperature environments is solved, and a higher sequencing throughput is achieved and accuracy.

CN119060983APending Publication Date: 2024-12-03BEIJING QITAN TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310650953.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-06-02
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

In the existing nanopore sequencing technology, the thermal stability of helicase in high temperature environments is insufficient, resulting in a decrease in sequencing performance, a decrease in accuracy and flux, making it difficult to effectively apply in high temperature environments in the wild.

Method used

By performing amino acid modification in the flexible region of the helicase, its thermal stability and sequencing performance are improved, for example, by modifying the Loop region and amino acid residues with higher B factor, the Tm value and sequencing performance of the helicase are enhanced.

Benefits of technology

Improve the thermal stability and sequencing performance of helicase, extend the sequencing time, increase the sequencing throughput and readout number, improve the accuracy and reliability of the data, and is suitable for applications in high temperature environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004266798640000161
    Figure BDA0004266798640000161
  • Figure BDA0004266798640000271
    Figure BDA0004266798640000271
  • Figure BDA0004266798640000272
    Figure BDA0004266798640000272
Patent Text Reader

Abstract

The invention belongs to the technical field of detection and characterization of target analytes, and particularly relates to a helicase mutant and application thereof, especially for nanopore sequencing. The helicase mutants of the present invention retain the ability to control the movement of polynucleotides through nanopores and have improved sequencing performance.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of detecting and characterizing target analytes, and specifically relates to a helicase mutant and an application thereof, in particular for nanopore sequencing. Background Art

[0002] With the research on nucleic acid structure and sequence, nucleic acid sequencing technology has been developing continuously and has become the core field of life science research, which has played a huge role in promoting the development of technology in biology, chemistry, electricity, life science, medicine and other fields. Using nanopores to develop new rapid, accurate, low-cost, high-precision and high-throughput nucleic acid sequencing technology is one of the hot spots of the post-human genome project.

[0003] Nanopore sequencing technology, also known as the fourth-generation sequencing technology, is a sequencing technology that uses target analytes such as single-stranded nucleic acid molecules as sequencing units. It uses a nanopore that can provide an ion current channel to allow target analytes such as single-stranded nucleic acid molecules to pass through the nanopore under the drive of an electric potential. When the target analyte passes through the nanopore, the current of the nanopore will be reduced, and the sequence information of the different signals generated will be read in real time.

[0004] The main features of nanopore sequencing are: long read length and high accuracy. Nanopore sequencing can not only realize natural DNA and RNA sequencing, but also directly obtain the base modification information of DNA and RNA. For example, it can directly read methylated cytosine without the need to treat the genome with bisulfite in advance as in the second-generation sequencing method. This has greatly promoted the direct study of epigenetic-related phenomena at the genome level. As a new platform, nanopore detection technology has the advantages of low cost, high throughput, and non-labeling.

[0005] When a potential is applied to a nanopore (transmembrane pore), an analyte such as a polynucleotide passing through the nanopore will produce a change in electrical signal. The nanopore detection of the analyte such as a polynucleotide can produce an electrical signal change of known signal and duration. In the chain sequencing method, an analyte such as a single polynucleotide chain passes through the nanopore and can achieve the identification of the nucleotide. The electrical signal changes caused by the passage of resolvable single-stranded DNA or RNA through the nanopore are recorded within the existing sampling range, which is largely due to the control of rate-controlling enzymes such as helicases to control or slow down the speed of DNA / RNA molecules passing through the nanopore.

[0006] In current sequencing systems, rate-controlling enzymes such as helicases are in a continuously heated sequencing environment. Long-term heating may cause obstacles to the coupling of ATP binding hydrolysis and helicase displacement, resulting in uneven or jammed enzyme movement speeds, or may cause the separation of helicases from single-stranded DNA due to enzyme denaturation, leading to reduced accuracy and throughput. On the other hand, a major advantage of the nanopore sequencing platform is its simplicity and portability, which allows real-time detection at any location according to user needs. In order to expand the application scenarios of the nanopore sequencing platform, such as high-temperature environments in the wild, helicases with higher thermal stability are needed.

[0007] Therefore, there is a need for a helicase with improved sequencing performance and / or with higher thermal stability. Summary of the invention

[0008] In order to solve the above technical problems, the present invention provides a helicase mutant and its application.

[0009] In a first aspect, the present invention provides a helicase mutant whose flexible region is rigidified and retains the ability to control the movement of a polynucleotide through a nanopore.

[0010] In one embodiment, the helicase mutant has improved sequencing performance, such as reduced sequencing speed, increased number of sequencing reads within the same sequencing time (or increased pore frequency), increased sequencing throughput and / or extended sequencing time, compared to the corresponding helicase without rigidification of the flexible region.

[0011] Reduced sequencing speed, increased sequencing flux, increased number of sequencing reads within the same sequencing time (or increased frequency of vias), and extended sequencing time are not necessarily all mutants that must simultaneously improve sequencing performance. Preferred mutants may have one or more of the above-mentioned performance improvements. Under similar sequencing speeds, some mutants will obtain more reads within the same sequencing time, thereby improving sequencing flux. Some mutants have reduced sequencing speeds, but the reduced speed may improve the accuracy of sequencing. The increase in the number of sequencing reads within the same sequencing time can make up for the reduced flux caused by the speed reduction, and even obtain a higher flux. In general, mutants with higher thermal stability (i.e., relatively high Tm values) are easier to keep working under heated sequencing conditions, can work normally for a longer time, and are also conducive to obtaining higher flux. A proper reduction in sequencing speed is more conducive to electrical signal analysis, and an extended sequencing time is conducive to increasing sequencing flux and increasing the amount of data, all of which are conducive to improving the accuracy of the analysis results.

[0012] In one embodiment, the flexible region is rigidified by one or more amino acid modifications at the loop region and / or the amino acid residues with higher B factors. In one embodiment, the amino acid residues with higher B factors are selected from the top 50, 40, 30, 20 or 10 amino acids with the highest B factors in the helicase sequence. In one embodiment, the amino acid residues with higher B factors are selected from the amino acid residues with the top 20%, 10%, 5%, 2% or 1% of the B factor values ​​in the helicase sequence. In one embodiment, the B factor is predicted using B-Fitter software.

[0013] In one embodiment, the helicase mutant has improved thermal stability compared to the corresponding helicase without rigid flexible region, and optionally the Tm value of the helicase mutant is increased by at least about 0.5°C, about 1°C, about 2°C, about 3°C, about 4°C, about 5°C, about 6°C, about 7°C, about 8°C, preferably at least about 10°C compared to the corresponding helicase without rigid flexible region. The thermal stability can be measured under locked enzyme or naked enzyme conditions.

[0014] In a preferred embodiment, the helicase mutant retains helicase activity, ATPase activity and substrate binding ability on the basis of improved thermostability.

[0015] In one embodiment, the corresponding helicase that has not been rigidified by the flexible region is a helicase of helicase superfamily 1 or superfamily 2 or a functional variant thereof, preferably a Pif1-like helicase, an Upf1-like helicase, an UvrD / Rep helicase, a Ski-like helicase, a Rad3 / XPD helicase, a NS3 / NPH-II helicase, a DEAD helicase, a DEAH / RHA helicase, a RecG-like helicase, a REcQ-like helicase, a T1R-like helicase, a Swi / Snf-like helicase or a Rig- I-like helicase or a functional variant thereof, more preferably a Pif1-like helicase, further preferably a Hel308 helicase or a functional variant thereof, a RecD helicase or a functional variant thereof, a TraI helicase or a functional variant thereof, an XPD helicase or a functional variant thereof, or a Dda helicase or a functional variant thereof, such as a T4-Dda helicase or a functional variant thereof, such as the Pif1-like helicase disclosed in CN113930406A, such as a Pectobacterium phage PM2 Pif1-like helicase (Uniprot ID: A0A0A0Q3A4), Acinetobacter phage Acj61 Pif1-like helicase (Uniprot ID: E5E403), Aeromonas phage PX29 Pif1-like helicase (Uniprot ID: E5DQH4), Cinqassovirus aeh1 Pif1-like helicase (Uniprot ID: Q76YI7), Serratia phage CBH8 Pif1-like helicase (Uniprot ID: A0A1Z1LY03), Edwardsiella phage PEi26 Pif1-like helicase (Uniprot ID: A0A0B6VP37), Acinetobacter phage AM101 Pif1-like helicase (Uniprot ID: E5E403), Aeromonas phage PX29 Pif1-like helicase (Uniprot ID: E5DQH4), Cinqassovirus aeh1 Pif1-like helicase (Uniprot ID: Q76YI7), Serratia phage CBH8 Pif1-like helicase (Uniprot ID: A0A1Z1LY03), Edwardsiella phage PEi26 Pif1-like helicase (Uniprot ID: A0A0B6VP37), Acinetobacter phage AM101 Pif1-like helicase (Uniprot ID: The corresponding helicase without rigidification of the flexible region can also be selected from the helicases shown in SEQ ID NO: 1 to SEQ ID NO: 21.

[0016] In one embodiment, the corresponding helicase without rigidification of the flexible region comprises the amino acid sequence shown in SEQ ID NO: 1 or comprises an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% identity with the amino acid sequence shown in SEQ ID NO: 1, and the helicase mutant has one or more amino acid modifications at the following positions corresponding to SEQ ID NO: 1: G158, S159, G161, A432 and G435. The amino acid modification includes deletion or substitution with other amino acids with larger side chains or stronger rigidity. For the G158 site, the optional amino acid modification includes deletion or replacement with P / N / Q; for the S159 site, the optional amino acid modification includes deletion or replacement with D / E / A / T / Y / N / Q; for the G161 site, the optional amino acid modification includes deletion or replacement with E / Q / T / I / V / L / S / M / N / Y; for the A432 site, the optional amino acid modification includes replacement with L / V / I / T / S / M / Y / N / Q / P / W / F; for the G435 site, the optional amino acid modification includes replacement with A / S / L / V / I / T / M / Y / N / Q / P / W / F. Preferably, the helicase mutant has one or more of the following amino acid modifications: ΔG158 / ΔS159, ΔG161, A432L, G435A.

[0017] In one embodiment, the corresponding helicase without rigidification of the flexible region comprises an amino acid sequence as shown in any one of SEQ ID NOs: 1-21 or an amino acid sequence having at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% identity with the amino acid sequence as shown in any one of SEQ ID NOs: 1. In one embodiment, the helicase mutant is selected from:

[0018] (a) A variant of the sequence shown in SEQ ID NO: 1, which has one or more amino acid modifications at the following sites: G158, S159, G161, A432, G435, V5-N11, R28-E31, P38-G42, G58-G61, A66-T68, G80-T85, K91, Y97-Q100, R106-N115, D120E121, L125D126, I137-C141, D148-S166, H171-S173, L179-A 187, G199-H204, D208G209, F215-A220, K233-E240, Y246T247, Y263-N271, Q278-P280, D288-G289, N298-N29 9. I316-K323, I336-I344, L350-L352, E371-P380, F391-K393, L397P398, Q406-N411, T417-D419, A423-E424;

[0019] (b) a variant of the sequence shown in SEQ ID NO: 2, which has one or more amino acid modifications at the following sites: G159, A160, E162, L428, G431, M1-T7, V24-R32, P39-G43, G59-G62, A67-T69, G81-T86, K92, Y98-S101, K107-R116, D121E122, Y126D127, I138-C142, D149-S166, H171-K173, L179- A187, G199-E204, D208G209, L215-S220, K233-E240, F246T247, Y263-D271, Q278-P280, E288G289, N298N29 9. S316-K323, L336-T342, I348-D350, S370-A376, F387-K389, L393P394, Q402-D407, T413-C415, A419D420;

[0020] (c) a variant of the sequence shown in SEQ ID NO: 3, which has one or more amino acid modifications at the following sites: G155, S156, Q158, A428, G431, I2-N8, R25-E28, , P35-G39, G55-G58, A63-T65, G77-T82, K88, Y94-Q97, R103-N112, D117E118, Y122D123, V134-C138, D145-S162, H167-K169, L175- A183, G195-D200, D204G205, F211-A216, K229-E236, Y242T243, Y259-P267, Q274-P276, E284G285, N294N29 5. R312-Q319, I332-V340, L346-E348, Q367-E376, F387-K389, L392P393, Q402-D407, T413-C415, A419E420;

[0021] (d) a variant of the sequence shown in SEQ ID NO: 4, which has one or more amino acid modifications at the following positions: G154, E155, E157, L425, G428, I2-T8, K25-G27, P34-G38, G54-G57, A62-T64, G76-T81, K87, Y93-N96, R102-R111, D116E117, Y121D122, V133-C137, D144-S161, H166-K168, L174-G 182. G194-E199, D203G204, F210-A215, K228-E235, Y241-T244, Y258-N266, Q273-P275, D283G284, N293N294 , S311-E318, A331-T339, I345-D347, N367-Y373, F384-K386, L390-P391, Q339-N404, T410-C412, A416D417;

[0022] (e) a variant of the sequence shown in SEQ ID NO: 5, which has one or more amino acid modifications at the following positions: G154, E155, E157, L427, G430, I2-T8, K25-N27, P34-G38, G54-G57, A62-T64, G76-T81, K87, Y93-S96, K102-R111, D116E117, W121D122, I133-C137, D144-S161, H166-D168, L174- A182, G194-E199, D203G204, F210-A215, K228-E235, Y241T242, Y258-V266, Q273-P275, E283G284, T293N29 4. G311-E318, Y331-R338, I344-D346, N366-Y374, F385-K387, L391P392, Q400-D405, T411-C413, S417S418;

[0023] (f) a variant of the sequence shown in SEQ ID NO: 6, which has one or more amino acid modifications at the following positions: G153, E154, T156, L425, G428, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, F209-A214, K227-E234, F240T241, F257-V265, Q272-P274, D282G283, N292N29 3. K310-E317, Y330-R337, I343-S345, N365-P373, F384-K386, L390P391, Q399-D404, T410-C412, A416D417;

[0024] (g) a variant of the sequence shown in SEQ ID NO: 7, which has one or more amino acid modifications at the following positions: G153, E154, T156, L425, G428, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, F209-A214, K227-E234, F240T241, F257-V265, Q272-P274, D282G283, N292N29 3. K310-E317, Y330-R337, I343-S345, N365-P373, F384-K386, L390P391, Q399-D404, T410-C412, A416D417;

[0025] (h) a variant of the sequence shown in SEQ ID NO: 8, which has one or more amino acid modifications at the following positions: G153, E154, T156, L425, G428, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, F209-A214, K227-E234, F240T241, F257-V265, Q272-P274, D282G283, N292N29 3. K310-E317, Y330-R337, I343-S345, N365-P373, F384-K386, L390P391, Q399-D404, T410-C412, A416D417;

[0026] (i) a variant of the sequence shown in SEQ ID NO: 9, which has one or more amino acid modifications at the following positions: G153, E154, T156, L423, G426, M1-T7, K24-H26, P33-G37, G53-G56, A61-T63, G75-T80, K86, Y92-N95, K101-R110, D115E116, C120D121, I132-C136, D143-S160, H165-K167, L173- A181, G193-D198, D202G203, Y209-D211, K224-E231, F237T238, L254-K262, Q269-P271, D279G280, N289N29 0. K307-E314, Y327-R335, I341-S343, F363-P371, F382-K384, L388P389, Q397-D402, T408-D410, A414D415;

[0027] (j) a variant of the sequence shown in SEQ ID NO: 10, which has one or more amino acid modifications at the following sites: G156, S157, E159, L429, G432, I2-K8, G25-Q29, P36-G40, G56-G59, A64-T66, G78-T83, K89, Y95-N98, K104-R113, D118E119, Y123D124, I135-C139, D146-S163, H168-D170, L176- A184, G196-D201, D205G206, F212-A217, K230-E237, F243T244, Y260-V268, Q275P276, E285G286, N295N296 , G313-E320, Y333-R341, I347-S349, N369-P377, F388-K390, L394-P395, Q403-D408, T414-C416, A420D421;

[0028] (k) a variant of the sequence shown in SEQ ID NO: 11, which has one or more amino acid modifications at the following positions: N156, S157, I159, L428, G431, L4-T10, K27-Q29, P36-G40, G56-G59, A64-T66, G78-T83, K89, Y95-A98, S104-R113, D118E119, Y123D124, V135-C139, D146-S163, N168-K170, L176 -A184, G196-E201, N205G206, M212-S219, K232-E239, F245T246, Y262-N270, Q277-P279, E287G288, N297N29 8. A315-E322, I335-V340, I346-D348, N368-N376, F387-K389, L393P394, Q402-D407, T413-C415, A419D420;

[0029] (l) A variant of the sequence shown in SEQ ID NO: 12, which has one or more amino acid modifications at the following sites: G155, D155, S158, L429, G432, I3-T9, K26-T28, P35-G39, G55-G58, A63-T65, G77-T82, K88, Y94-N97, K103-R112, D117E118, W122D123, I134-C138, D145-S162, H167-D169, L175 -A183, G195E200, D204G205, F211-A216, K229-E236, F242T243, Y259-A267, Q274-P276, D284G285, N294N29 5. G312-E319, Y332-R340, I346-D348, N368-P376, F387-K389, L393P394, Q402-D407, T413-C415, S419N420;

[0030] (m) a variant of the sequence shown in SEQ ID NO: 13, which has one or more amino acid modifications at the following sites: G155, S156, V158, L428, G431, I2-N8, G25-N28, P35-G39, G55-G58, A63-T65, G77-T82, K88, Y94-S97, K103R112, D117E118, Y122D123, I134-C138, D145-S162, H167-D169, L175- A183, G195-D200, D204G205, F211-A216, K229-E236, F242T243, L259-T267, Q274-P276, E284G285, N294N29 5. S312-E319, Y332-L340, I346-D348, N368-P376, F387-K389, L393P394, Q402-D407, T413-C415, A419D420;

[0031] (n) a variant of the sequence shown in SEQ ID NO: 14, which has one or more amino acid modifications at the following positions: G150, S151, V153, L423, G426, M1-N3, G20-G23, P30-G34, G50-G54, A58-T60, G72-T77, K83, Y89-N92, K98-R107, D112E113, Y117D118, I129-C133, D140-S157, H162-D164, L170- A178, G190-E195, D199G200, F206-A211, K224-E231, F237T238, F254-V262, S269-P271, D279-G280, N289N2 90. G307-E314, Y327-R335, I341-D343, N363-P371, Y382-K384, L388P389, Q397-D402, T408C410, A414D415;

[0032] (o) a variant of the sequence shown in SEQ ID NO: 15, which has one or more amino acid modifications at the following positions: G153, D154, L156, A427, S430, M1-T7, K24-H26, P33-G37, G53-G57, A61-T63, G75-T80, K86, Y92-E95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, H165-R167, L173- G181, G193-E198, D202G203, F209-P214, K227-E234, Y240T241, Y257-V265, Q272-P274, D282G283, N292N29 3. K310-K317, V330-R338, L344-D346, E366-H375, F386-K388, L392P393, Q401-D406, T412-C414, A418D419;

[0033] (p) a variant of the sequence shown in SEQ ID NO: 16, which has one or more amino acid modifications at the following positions: G156, S157, G159, A430, G433, L3-K9, R26-G29, P36-G40, G56-G60, A64-T66, G78-T83, K89, Y95-Q98, R104-N113, D118E119, Y123G124, V135-C139, D146-S164, H169-S171, L177- T185, G197-E202, D206G207, F213-A218, K231-E238, F244T245, Y261-K269, Q276-P279, D286G287, N296N29 7. S314-R321, A334-V342, L348-A350, E369-P378, F389-K391, L395P396, Q404-N409, T415-C417, A421E422;

[0034] (q) a variant of the sequence shown in SEQ ID NO: 17, which has one or more amino acid modifications at the following positions: G153, D154, L156, A427, S430, M1-T7, K24-F26, P33-G37, G53-G57, A61-T63, G75-T80, K86, Y92-E95, K101-R110, D115E116, Y120D121, I132-C136, D143-S160, D165-R167, L173- G181, G193-E198, D202G203, F209-P214, K227-E234, Y240T246, Y257-V265, Q272-P274, D282G283, N292N29 3. K310-K317, V330-R338, L340-D346, E366-H375, F386-K388, L392P393, Q401-D406, T412-C414, A418D419;

[0035] (r) a variant of the sequence shown in SEQ ID NO: 18, which has one or more amino acid modifications at the following positions: N155, S156, G158, T429, G432, I3-T9, K26-K28, P35-G39, G55-G59, A63-T65, G77-T82, K88, Y94-N97, K103-R112, D117E118, Y122D123, I134-C138, D145-S163, D168-R170, L176- S184, G196-H201, D206G207, Y213-A219, R232-E239, Y245-T247, Y262-V270, Q277-P279, E287G288, H297N29 8. R315-E322, N335-R343, L349-D351, S371-H377, F388-K390, L394P395, Q403-D408, T414-C416, A420D421;

[0036] (s) a variant of the sequence shown in SEQ ID NO: 19, which has one or more amino acid modifications at the following sites: N167, S167, T170, L438, G441, L4-T10, K27-P40, P47-G51, G67-G70, A75-T77, G89-T94, K100, Y106-S109, S115-R124, D129E130, Y134D135, I146-C150, D157-S174, N179-K181, L18 7-A195, G207-E212, D216G217, M223-S230, K243-D250, F256T257, Y273-K281, Q288-P290, E298-G299, N308N3 09. F326-S333, V346-V351, I357-D359, N379-N386, F397-K399, L403P404, Q412-D417, T423-C425, A429D430;

[0037] (t) a variant of the sequence shown in SEQ ID NO: 20, which has one or more amino acid modifications at the following sites: L426, G429, I2-T8, A25-K37, P44-G48, G64-G67, A72-T74, G86-T91, K97, Y103-K106, S112-R121, E126E127, Y131D132, I143-T147, D154-S167, D172-R174, L180-M188, G 200-E205, D209D210, D216-S218, K231-E238, Y244T245, Y261-V269, Q276-P278, E286G287, N296N297, K 314-Q321, I334-S339, I345-D347, S367-F373, Y384-R386, L390P391, Q399-D404, T410-C412, Y416A417;

[0038] (u) a variant of the sequence shown in SEQ ID NO: 21, which has one or more amino acid modifications at the following positions: G158, S159, G161, A432, G435, V5-N11, R28-E31, P38-G42, G58-G61, A66-T68, G80-T85, K91, Y97-Q100, R106-N115, D120E121, L125D126, I137-C141, D148-S166, H171-S173, L179- A187, G199-H204, D208G209, F215-A220, K233-E240, F246T247, Y263-N271, Q278-P280, D288-G289, N298-N29 9. I316-K323, I336-I344, L350-L352, E371-P380, F391-K393, L397P398, Q406-N411, T417-C419, A423-E424.

[0039] In a second aspect, the present invention provides a polynucleotide encoding the helicase mutant of the first aspect.

[0040] In a third aspect, the present invention provides a vector comprising the polynucleotide of the second aspect.

[0041] In a fourth aspect, the present invention provides a host cell comprising the vector of the third aspect.

[0042] Any host cell known in the art that is suitable for protein expression can be used as the host cell of the present invention, such as Escherichia coli cells.

[0043] In a fifth aspect, the present invention provides a kit comprising the helicase mutant of the first aspect.

[0044] In a sixth aspect, the present invention provides a method for improving the thermal stability of a helicase, the method comprising rigidifying a flexible region of the helicase.

[0045] In a seventh aspect, the present invention provides a method for producing the helicase mutant of the present invention, comprising transforming the host cell of the fourth aspect with the vector of the third aspect, and inducing the host cell to express the helicase mutant of the first aspect.

[0046] In an eighth aspect, the present invention provides a method for determining the presence, absence or one or more characteristics of a target analyte, the method comprising:

[0047] (a) contacting the target analyte with a nanopore and a helicase mutant of the first aspect, such that the helicase mutant controls movement of the target analyte through the pore;

[0048] (b) applying an electric potential across the pore to cause the target analyte to migrate through the pore; and

[0049] (c) obtaining one or more characteristics of the target analyte when interacting with the pore to obtain the presence, absence or one or more characteristics of the target analyte.

[0050] In one embodiment, the target analyte is preferably a polysaccharide, a metal ion, an inorganic salt, a polymer, an amino acid, a peptide, a polypeptide, a protein, a nucleotide, an oligonucleotide, a polynucleotide, a dye, a drug, a diagnostic agent, an explosive or an environmental pollutant; or, the target analyte is selected from one or more of a polynucleotide, a polypeptide, a polysaccharide and a lipid, preferably a polynucleotide or a polypeptide, a polysaccharide and a lipid connected to a polynucleotide, more preferably a single-stranded polynucleotide, a double-stranded polynucleotide or a partially double-stranded polynucleotide. The method may involve determining the presence, absence or one or more properties of two or more target analytes of the same class, for example, two or more proteins, two or more nucleotides or two or more drugs. Alternatively, the method may involve determining the presence, absence or one or more properties of two or more target analytes of different classes, for example, one or more proteins, one or more nucleotides and one or more drugs. One or more properties include, but are not limited to, for example, the length, identity, specific sequence, secondary structure and modification (methylation, oxidation, damage, marker, tag or spacer modification, etc.) of the target analyte polynucleotide.

[0051] In one embodiment, the method of the eighth aspect can reduce sequencing speed, increase sequencing throughput and / or extend sequencing time.

[0052] In a preferred embodiment, the method of the eighth aspect is a nanopore sequencing method.

[0053] In a ninth aspect, the present invention provides use of the helicase mutant of the first aspect for analyzing the presence, absence or one or more characteristics of a target analyte.

[0054] In a preferred embodiment, the use of the ninth aspect is nanopore sequencing. BRIEF DESCRIPTION OF THE DRAWINGS

[0055] Figure 1a The Coomassie Brilliant Blue staining results of the helicase mutant of the present invention and the corresponding helicase without rigidification of the flexible region (control, M2) are shown.

[0056] Figure 1bThe thermal stability of the helicase mutant of the present invention and the corresponding helicase (control, M2) without rigidification of the flexible region under locked enzyme conditions is shown. The Tm value of the protein was detected by the protein thermal shift curve method. The statistical method of One-way ANOVA was used for statistics, and the representative experiments, mean and SEM are shown in the figure. * indicates P < 0.05, ** indicates P < 0.005, *** indicates P < 0.0005, and **** indicates P < 0.0001.

[0057] Figure 1c The helicase activity of the helicase mutant of the present invention and the corresponding helicase (control, M2) without rigidification of the flexible region in the locked enzyme state in high salt buffer and at room temperature is shown. The statistical method of One-way ANOVA was used for statistics, and the representative experiments, mean and SEM are shown in the figure. * is P<0.05, ** is P<0.005, *** is P<0.0005, **** is P<0.0001.

[0058] Figure 1d The figure shows the ADP contained in the HPLC detection system after the helicase mutant of the present invention and the corresponding helicase without rigidification of the flexible region (control, M2) were locked with the substrate ssDNA-M13 and incubated in a high salt buffer (10mM HEPES 7.0, 675mM KCl, 25mM MgCl2, 25mMATP) at 34°C for 2h, which reflects the ATPase activity of the helicase. Each mutant was normalized relative to M2.

[0059] Figure 1e The figure shows the TBE-native gel electrophoresis of the helicase mutant of the present invention and the corresponding helicase without rigidification of the flexible region (control, M2) in the locked enzyme state in a high salt buffer (10mM HEPES 7.0, 675mM KCl) at 34°C for 0 hours (upper figure) and 1 hour (lower figure). The arrow indicates ssDNA-T44-HEX, and the brackets indicate the substrate bound to the enzyme.

[0060] Figure 2a -d shows the sequencing performance of the helicase mutant of the present invention and the corresponding helicase (control, M2) without rigidification of the flexible region, which was mixed and tested on a Qnome-3841 sequencer at 38°C for 24 hours with the same input amount. Figure 2a The relative read numbers are shown, and it can be seen that the read numbers of the mutants of the present invention are significantly increased compared to the control; Figure 2b shows the relative flux, Figure 2c The sequencing speed is shown; Figure 2d The distribution of sequencing speed over time is shown. DETAILED DESCRIPTION

[0061] It will be understood that different applications of the disclosed products and methods can be adapted according to the specific needs of the art.It will also be understood that the terminology used herein is for the purpose of describing particular embodiments of the present invention only and is not intended to be limiting.

[0062] General Definition

[0063] Additionally, as used in the specification and claims, the singular forms "a", "an", and "the" include pluralities unless the context clearly dictates otherwise. For example, reference to "a helicase" includes two or more helicases.

[0064] As used herein, the terms "comprising," "including," and "having" mean that any listed elements must be included, and other elements may also be optionally included. "Consisting of" means that all unlisted elements are not included. Embodiments defined by each of these terms are within the scope of the present invention.

[0065] As used herein, the term "about" in connection with all numerical values ​​(including the lower and upper limits of numerical ranges) means any value with an acceptable variation of up to ±10% (e.g., ±0.5%, ±1%, ±1.5%, ±2%, ±2.5%, ±3%, ±3.5%, ±4%, ±4.5%, ±5%, ±5.5%, ±6%, ±6.5%, ±7%, ±7.5%, ±8%, ±8.5%, ±9%, ±9.5%).

[0066] As used herein, the term "high temperature" refers to a temperature above room temperature, for example above 20°C, above 25°C, above 30°C, above 40°C, above 50°C, above 60°C.

[0067] As used herein, the term "retaining helicase activity, ATPase activity and substrate binding ability" means that the helicase activity, ATPase activity and substrate binding ability are improved compared to the corresponding helicase without rigidification of the flexible region, for example, by at least 1.1 times, 1.2 times, 1.3 times, 1.4 times, 1.5 times, 2 times or 3 times; or there is no significant change, that is, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% of the enzymatic activity of the corresponding helicase without rigidification of the flexible region is retained.

[0068] As used herein, the term "increased sequencing throughput" refers to an increase in sequencing throughput of at least 1.5 times, at least 2 times, at least 5 times, at least 10 times, at least 15 times compared to the corresponding helicase without rigidification of the flexible region.

[0069] As used herein, the term "naked enzyme" refers to a helicase that is not locked with a substrate, and a "locked enzyme" refers to a helicase that is locked with a substrate. In one embodiment, the locking enzyme forms a connection such as a covalent crosslink in the Pin-Tower region of the helicase, so that the helicase is in a conformational state that is more conducive to unwinding, and at the same time, the substrate single-stranded DNA is enclosed in the arch formed by the protein and the Pin-Tower crosslink, ensuring that the enzyme does not fall off the ssDNA, thereby ensuring the continuity of sequencing. Methods for locking with substrates are known in the art, and can be found in WO2021253410A1.

[0070] As used in this article, the term "mixed testing" means that different enzymes are used to build libraries with different sequences, which are then mixed together and added to the same chip for sequencing, eliminating the impact of different chips on sequencing. The term "sequencing speed" refers to the length of the sequence to be tested divided by the time required for it to pass through the nanopore. The term "sequencing read number" refers to the number of sequences to be tested read by the sequencer. The term "sequencing throughput" refers to the number of bases of the sequence to be tested that pass through the nanopore within a certain period of time.

[0071] In the context of the present disclosure, the term "amino acid" is used in its broadest sense and is intended to include organic compounds containing amine (NH2) and carboxyl (COOH) functional groups and side chains (e.g., R groups) that are unique to each amino acid. In some embodiments, amino acids refer to naturally occurring Lα-amino acids or residues. Common single-letter and three-letter abbreviations for naturally occurring amino acids are used herein: A = Ala; C = Cys; D = Asp; E = Glu; F = Phe; G = Gly; H = His; I = Ile; K = Lys; L = Leu; M = Met; N = Asn; P = Pro; Q = Gln; R = Arg; S = Ser; T = Thr; V = Val; W = Trp; and Y = Tyr (Lehning er, AL, (1975) Biochemistry, 2nd edition, pages 71-92, Worth Publishers, New York). The general term "amino acid" also includes D-amino acids, retro-inverse amino acids, and chemically modified amino acids (such as amino acid analogs), naturally occurring amino acids that are not usually incorporated into proteins (such as norleucine), and chemically synthesized compounds with properties known in the art to be characteristic of amino acids (such as β-amino acids). For example, analogs or mimetics of phenylalanine or proline are included in the definition of amino acids, which allow the same conformational restrictions on peptide compounds as natural Phe or Pro. Such analogs and mimetics are referred to herein as "functional equivalents" of the corresponding amino acids. Roberts and Vellaccio, The Peptides: Analysis, Synthesis, Biology, Gross and Meiehofer, eds., Vol. 5, p. 341, Academic Press, Inc., NY 1983, list other examples of amino acids, which are incorporated herein by reference.

[0072] The terms "protein", "polypeptide" and "peptide" are further used interchangeably herein to refer to polymers of amino acid residues as well as variants and synthetic analogs of amino acid residues. Thus, these terms apply to amino acid polymers in which one or more amino acid residues is a synthetic non-naturally occurring amino acid, such as a chemical analog of a corresponding naturally occurring amino acid, as well as to naturally occurring amino acid polymers. Polypeptides may also undergo maturation or post-translational modification processes, which may include, but are not limited to, glycosylation, proteolytic cleavage, lipidation, signal peptide cleavage, propeptide cleavage, phosphorylation, and the like.

[0073] The term "wild type" refers to a gene or gene product isolated from a naturally occurring source. A wild-type gene is the gene most commonly observed in a population and is therefore arbitrarily designed to be the "normal" or "wild-type" form of the gene. In contrast, the term "mutant," "modified" or "variant" refers to a gene or gene product that exhibits sequence modifications (e.g., replacements, truncations or insertions), post-translational modifications and / or functional properties (e.g., property changes) compared to a wild-type gene or gene product. "Amino acid modifications" herein include, for example, amino acid insertions, deletions and / or substitutions.

[0074] Conservative substitutions replace amino acids with other amino acids with similar chemical structures, similar chemical properties, or similar side chain volumes. The introduced amino acids may have similar polarity, hydrophilicity, hydrophobicity, alkalinity, acidity, neutrality, or charge as the amino acids they replace. Alternatively, conservative substitutions may introduce another aromatic or aliphatic amino acid to replace a pre-existing aromatic or aliphatic amino acid. Conservative amino acid changes are well known in the art, and it is well known that conservative substitutions of similar amino acids do not usually affect the activity of the peptide sequence, and conservative substitutions are shown in Table 1.

[0075] Table 1 Conservative amino acid substitutions

[0076]

[0077] The sequence homology or identity of amino acid or polynucleotide sequences can be determined by standard alignment algorithms and can be used with the default gap penalty established by the program used. For example, homology, similarity or identity can be determined using BLAST or ClustalW of the National Center for Biotechnology Information (NCBI).

[0078] Rate-controlling enzymes and helicases

[0079] The rate-controlling enzyme can be any protein that can bind to polynucleotide and control its movement through hole. The rate-controlling enzyme often interacts with polynucleotide and modifies at least one property of polynucleotide. The enzyme can modify it by cracking polynucleotide to form a short chain (for example, dinucleotide or trinucleotide) of each single nucleotide or nucleotide. The enzyme can modify it by orienting the polynucleotide or moving it to a specific position. The rate-controlling enzyme does not need to show enzymatic activity, as long as it can bind to polynucleotide and control its movement through hole. For example, the enzyme can be modified to remove its enzymatic activity, or it can be used under conditions that prevent it from being used as an enzyme.

[0080] The rate-controlling enzyme is preferably a polymerase, an exonuclease, a helicase and a topoisomerase, such as a gyrase. In one embodiment, the enzyme is preferably a helicase, which may be a member of, for example, a helicase superfamily 1 (SF1) or superfamily 2 (SF2). The catalytic cores of SF1 and SF2 helicases have almost identical folds and extensive structural similarities, consisting of two similar protein domains, similar to the fold of the recombinant protein RecA, which can be further classified as Pif1-like helicase, Upf1-like helicase, UvrD / Rep helicase, Ski-like helicase, Rad3 / XPD helicase, NS3 / NPH-II helicase, DEAD helicase, DEAH / RHA helicase, RecG-like helicase, REcQ-like helicase, T1R-like helicase, Swi / Snf-like helicase and Rig-I-like helicase (see, e.g., Fairman-Williams ME et al., Curr Opin Struct Biol. 2010 Jun; 20(3):313-24.).

[0081] Pif1-like helicases belong to the SF1B helicase (5'-3'), including Dda from bacteriophage T4, RecD2 from bacteria, Pif1 from eukaryotes, and human DNA helicase B. This family of helicases is usually composed of 1A, 2A, 1B, and 2B domains, and unwinds and translocates along the 5'-3' direction with single-stranded DNA as a substrate. The conserved motifs MotifI-VI of the 1A and 2A domains constitute the ATP binding pocket, and the 1B and 2B domains together with the 1A and 2A domains form a nucleic acid binding channel. The cycle of ATP binding, hydrolysis, release, and rebinding is coupled to the opening and closing of its nucleic acid binding channel and the translocation movement on the single-stranded nucleic acid. Each consumption of an ATP causes the helicase to move one step toward the 3' end on the single-stranded DNA. This enables us to obtain a current signal step corresponding to the nucleotide sequence.

[0082] In a preferred embodiment of the present invention, the helicase is a Pif1-like helicase, or is selected from Hel308 helicase or a functional variant thereof, RecD helicase or a functional variant thereof, TraI helicase or a functional variant thereof, XPD helicase or a functional variant thereof, Dda helicase or a functional variant thereof, Edwardsiella phage PEi26 Pif1-like helicase or a functional variant thereof.

[0083] The flexible region rigidification strategy of the present invention can be used to transform any known helicase with sequencing activity. In this article, "corresponding helicase without flexible region rigidification" includes any wild-type SF1 or SF2 wild-type helicase that can control the movement of polynucleotides, and functional variants thereof. "Functional variant" of the helicase of the present invention refers to a helicase with conservative or non-conservative amino acids or nucleotides inserted, deleted or replaced at one or more positions, but retains the helicase that controls the movement activity of polynucleotides. Helicases and functional variants thereof that can be used for sequencing are known in the art, for example, see CN107109380A, WO2021253410A1, US20150065354A1, EP2875128B1, etc. For example, it is known in the art that the sustainable sequencing ability of a protein can be improved by modifying and transforming the protein, for example, introducing specific amino acid residues (Cys or non-natural amino acids) on domains such as 1A and 2A, and locking it on a nucleic acid linker before sequencing for "locking enzyme". For the method of "locking enzyme", please refer to WO2021253410A1. There may be other alternative ways to lock enzyme now or in the future.

[0084] Rigidization of flexible areas

[0085] The loop region is a potential flexible region in the protein structure and an important region for regulating enzyme catalytic activity, stability, and substrate specificity. It includes well-defined turns and more disordered random coils, which usually connect major secondary structures such as α-helices and β-folds. The loop region is an important structural element in proteins and usually has higher sequence variability between homologs, thus contributing to the diversification of functions within different evolutionary branches of the same superfamily. More and more studies have shown that the loop region plays an important role in regulating enzyme catalysis, specificity, stability, and protein-protein interactions. A loop region that is too long may have a negative impact on protein folding. The flexible region can be rigidified by truncating the amino acid sequence of the loop region.

[0086] In addition, the flexible region can be rigidified according to the amino acid preference of the most common secondary structure β-turn in the loop region. The β-turn is composed of 4 amino acids (i, i+1, i+2, i+3) and is divided into classes I-IX according to the dihedral angles of the i+1 and i+2 amino acids. Studies have shown that among the β-turns of the 426 proteins counted, Pro, Met, and Trp have a higher probability of occurrence, while Val, Gly, Ala, and Gln have a lower probability of occurrence. At the same time, the frequency of certain fixed amino acid residues appearing at different positions of the structure also varies. For example, Pro prefers to be at the i+1 position in type I and type II, and Gly prefers to be at the i+3 position in type I and the i+2 position in type II. In type II β-turn, the preference statistics of amino acid residues at different positions are as follows: i: Cys, Pro; i+1: Ala, Gln, Lys, Pro; i+2: Gly, Asn; i+3: Cys, Asp, Lys, Gln, Ser, Tyr.

[0087] The development of structural biology and bioinformatics has made it possible to more accurately locate the flexible sites of proteins through analysis of some structural parameters (such as B factor, RMSF value, Gibbs free energy, etc.) or homologous sequence comparison.

[0088] The B factor, also known as the temperature factor, reflects the "ambiguity" of the atomic electron density in the crystal. The greater the "ambiguity", the more unstable the conformation of the corresponding site. Since the B factor is derived from the crystal structure, it reflects the static stability of the protein. Different algorithms, such as canonical mode analysis, elastic network model, Gaussian network model, flexibility and rigidity index method, and multi-scale weighted color map model, have been developed to accurately predict protein B factors. Protein B factors can also be obtained through the B-factor database (BDB) database (http: / / www.cmbi.ru.nl / bdb / ) or using computational tools such as B-FITTER and YASARA. B-factor spectra have been shown to be effective in analyzing flexible sites of proteins. However, the use of B factors also has some restrictions or limitations. Accurate prediction of protein B factors requires high protein structure quality. Depending on the structural refinement and crystal quality, the B-factor values ​​between proteins may vary greatly.

[0089] RMSF / RMSD is obtained through molecular dynamics simulation, which reflects the dynamic stability of the protein. In addition, the stable state of a protein is generally the state with the minimum Gibbs free energy. Therefore, the Gibbs free energy of the protein conformation can be predicted by software such as Rosetta / Fold X to determine the effect of different sites on the stability of the protein conformation. Through multiple sequence alignment of homologous proteins, some sites with differences in homologous protein sequences from high-temperature resistant species can be found as candidate sites and mutation directions for improving thermal stability.

[0090] However, the strategy of rigidifying flexible regions currently has a low success rate. First, there is still limited knowledge about how to determine the best candidate sites for mutation. Second, there is a restrictive relationship between the catalytic activity and stability of the enzyme: the rigidity of the structure determines the thermal stability, while the flexibility determines the catalytic activity. Mutants with higher thermal stability tend to have lower catalytic activity. In order to realize the utilization value of enzymes under high temperature conditions, it is obviously not advisable to improve thermal stability at the expense of enzyme catalytic activity.

[0091] The inventors unexpectedly discovered that the helicase mutants of the present invention retain the ability to control the movement of polynucleotides through the nanopore after the flexible region is rigidified, and have improved sequencing performance, for example, the sequencing speed can be reduced, the number of sequencing reads can be increased within the same sequencing time, the sequencing time can be extended, the sequencing throughput can be increased, or the sequencing accuracy can be improved.

[0092] In addition, the helicase mutants of the present invention can have improved thermal stability while retaining helicase activity, ATPase activity and substrate binding ability. The helicase activity of the mutant can be measured in a variety of ways, such as the fluorescence analysis method described in the examples. The ATPase activity of the mutant can be measured using radiolabeling or by quantitative phosphate consumption as described in the examples. The determination method of the substrate binding ability of the mutant includes but is not limited to fluorescence anisotropy, tryptophan fluorescence and gel mobility shift assay EMSA.

[0093] Polynucleotides, vectors, host cells

[0094] The present invention provides a polynucleotide encoding the helicase mutant of the present invention, a vector comprising the polynucleotide, and a host cell comprising the vector.

[0095] Any protein described herein can be expressed using methods known in the art. Polynucleotide sequences can be isolated and replicated using standard methods in the art. DNA encoding a helicase can be isolated from an organism that produces a helicase, such as a T4 bacteriophage. PCR with specific primers can be used to amplify the gene encoding sequence of interest. The amplified sequence can then be inserted into a recombinant replication vector such as a cloning vector. The vector can be used to replicate the polynucleotide in a compatible host cell. Therefore, a polynucleotide sequence can be prepared by introducing a polynucleotide encoding a sequence of interest into a replicable vector, including introducing the vector into a compatible host cell, and growing the host cell under conditions that cause the vector to replicate. The vector can be recovered from the host cell.

[0096] The polynucleotide sequence can be cloned into an appropriate expression vector. In the expression vector, the polynucleotide sequence is usually operably linked to a control sequence that can provide for the expression of the coding sequence by the host cell.

[0097] The term "operably linked" refers to a juxtaposition wherein the various components described are in a relationship permitting them to function in their intended manner. A control sequence "operably linked" to a coding sequence is linked under conditions compatible with the control sequences in a manner that achieves expression of the coding sequence. Multiple copies of the same or different polynucleotides may be introduced into a vector.

[0098] The vector can be, for example, a plasmid, virus or phage vector with a replication origin, optionally a promoter for expressing the polynucleotide sequence, and optionally a regulatory factor for the promoter. The vector can contain one or more selectable marker genes, such as an ampicillin resistance gene. Promoters and other expression control signals compatible with the host cell (for which the vector is designed) can be selected. T7, trc, lac, ara or k promoters are usually used.

[0099] The host cell usually expresses the enzyme at a high level. A host cell compatible with the vector used to transform the host cell is selected for polynucleotide sequence transformation. The host cell is usually bacterial and preferably Escherichia coli. Any cell with a lambda DE3 lysogen, such as Rosetta2(DE3)pLys, C41(DE3), BL21(DE3), JM109(DE3), B834(DE3), TUNER, Origami and Origami B, can express a vector containing a T7 promoter.

[0100] Reagent test kit

[0101] The present invention also provides a kit for characterizing a target analyte (e.g., a target polynucleotide), comprising the helicase mutant of the present invention. The kit may also comprise components for forming a nanopore or membrane, such as a phospholipid required for forming an amphiphilic layer (e.g., a lipid bilayer).

[0102] The kit may additionally include one or more other reagents or instruments that enable any of the embodiments mentioned above to be performed. Such reagents or instruments include one or more of the following: a suitable buffer (aqueous solution), a device for obtaining a sample from an individual (such as a container or instrument comprising a needle), a device for amplifying and / or expressing polynucleotides, or a voltage or patch clamp device. The reagent may be present in the kit in a dry form so that the fluid sample resuspends the reagent. The kit may also optionally include instructions that enable the use of the kit with the method of the present invention or details on which organism the method can be used.

[0103] Device

[0104] The present invention also provides a device for characterizing a target analyte (e.g., a target polynucleotide), comprising a helicase mutant of the present invention. The device preferably also includes instructions for implementing the method in the embodiment. The device can be any conventional device for analyte analysis, such as an array or a chip. The device can also include any features present in the kit described herein.

[0105] In one embodiment, the device comprises: a sensor device capable of supporting a plurality of pores and operable to use the pores and a helicase to characterize a polynucleotide; and at least one port for delivering a material for characterization. In one embodiment, the device comprises: a sensor device capable of supporting a plurality of pores and operable to use the pores and a helicase to characterize a polynucleotide; and at least one memory for storing a material for characterization; a fluidics system configured to controllably provide material to the sensor device from the at least one memory; and one or more containers for receiving corresponding samples, the fluidics system being configured to selectively provide samples from one or more containers to the sensor device.

[0106] The device may be any one of those described in WO2009 / 077734, WO2010 / 122293, WO2011 / 067559 or WO00 / 28312. The device may specifically be a gene sequencer QNome-9604 or QNome-3841 from Qi Carbon Technology.

[0107] hole

[0108] The pores are structures that allow hydrated ions to flow from one side of the membrane to the other layer of the membrane driven by an applied electric potential.

[0109] Further preferably, the pore is a nanopore, and the nanopore is a transmembrane pore. The transmembrane pore provides a channel for the movement of the target polynucleotide. Further preferably, the pore is selected from a biological pore, a solid-state pore, or a biological and solid-state hybrid pore.

[0110] In some specific embodiments, the pores include but are not limited to those derived from Mycobacterium smegmatis porin A (MspA), Mycobacterium smegmatis porin B, Mycobacterium smegmatis porin C, Mycobacterium smegmatis porin D, hemolysin, lysin, interleukin, outer membrane porin F, outer membrane porin G, outer membrane phospholipase A, CSGG, WZA or Neisseria autotransporter lipoprotein; graphene nanopore, MoS2 nanopore, BN nanopore or PA63 nanopore, optionally, the pore is selected from MspA nanopore or CSGG nanopore.

[0111] Methods for determining the presence, absence or one or more characteristics of a target analyte

[0112] The present invention also provides a method for determining the presence, absence or one or more characteristics of a target analyte, the method comprising using a helicase mutant of the present invention. The one or more characteristics are preferably selected from (i) the length of the polynucleotide, (ii) the identity of the polynucleotide, (iii) the sequence of the polynucleotide, (iv) the secondary structure of the polynucleotide, and (v) whether the polynucleotide is modified. In one embodiment, any combination of (i) to (v) can be measured.

[0113] For (i), the length of the polynucleotide may be measured, for example, by determining the number of interactions between the polynucleotide and the pore or the duration of interactions between the polynucleotide and the pore.

[0114] With respect to (ii), the identity of a polynucleotide can be measured in a variety of ways, and the identity of a polynucleotide can be measured in conjunction with or without measurement of the polynucleotide sequence. The former is relatively simple; the polynucleotide is sequenced and identified. The latter can be accomplished in several different ways. For example, the presence of a particular motif in a polynucleotide can be measured (without measuring the rest of the sequence of the polynucleotide). Alternatively, the measurement of a specific electrical and / or optical signal in the method can identify that the polynucleotide is from a particular source.

[0115] For (iii), the sequence of the polynucleotide can be determined as previously described. Suitable sequencing methods, in particular sequencing methods using electrical measurement methods, are described in Stoddart D et al., ProC Natl Acad Sci, 12; 106 (19) 7702-7, Lieberman KR et al., J Am Chem SoC. 2010; 132 (50) 17961-72 and WO2000 / 28312.

[0116] For (iv), secondary structure can be measured using a variety of methods. For example, if the method involves an electrical measurement method, the secondary structure can be measured using a change in residence time or a change in the current flowing through the pore. This allows for the differentiation of regions of single-stranded and double-stranded polynucleotides.

[0117] For (v), the presence or absence of any modification may be measured. The method preferably comprises determining whether the polynucleotide is modified by methylation, oxidation, damage, treatment with one or more proteins or with one or more markers, tags or is abasic or lacking nucleobases and sugars. Specific modifications will result in specific interactions with the pore, which can be measured using the following methods. For example, methylcytosine can be distinguished from cytosine based on the current flowing through the pore during its interaction with each nucleotide.

[0118] In one embodiment, the method includes electrical measurement and optical measurement. Electrical measurement includes voltage measurement, capacitance measurement, current measurement, impedance measurement, tunneling measurement (Ivanov AP et al., Nano Lett. 2011 Jan 12; 11 (I): 279-85) and FET measurement (International Application WO 2005 / 124888). Optical measurement can be combined with electrical measurement (Soni GV et al., Rev Sci Instrum. 2010 Jan; 81 (1) 014301). The measurement can be a transmembrane current measurement, such as a measurement of an ion current flowing through the pore. In one embodiment, electrical measurement or optical measurement can be conventional electrical or optical measurement. Electrical measurements can be performed using standard single-channel recording equipment as described in Stoddart D et al., ProC Natl Acad Sci, 12; 106 (19) 7702-7, Lieberman KR et al, J Am Chem SoC. 2010; 132 (50) 17961-72 and international application WO 2000 / 28312. Alternatively, electrical measurements can be performed using a multi-channel system, such as described in international application WO2009 / 077734 and international application WO 2011 / 067559.

[0119] The method is preferably performed using a potential applied across the membrane. The applied potential may be a voltage potential. Alternatively, the applied potential may be a chemical potential. An example of this is the use of a salt gradient across the membrane, such as a layer of amphiphilic molecules. Salt gradients are disclosed in Holden et al., J Am Chem SoC. 2007 Jul 11; 129(27): 8650-5. In some cases, the current flowing through the mutant / protein pore of the protein monomer as the polynucleotide moves relative to the mutant / protein pore of the protein monomer is used to estimate or determine the sequence of the polynucleotide. This is strand sequencing.

[0120] The method may include measuring the current flowing through the hole when the polynucleotide moves relative to the hole. Therefore, the equipment used for the method may also include a circuit capable of applying an electric potential and measuring the electrical signal passing through the membrane and the hole. The method may be performed using a patch clamp or a voltage clamp.

[0121] Can comprise measuring the current flowing through described hole when polynucleotide moves relative to described hole.Suitable conditions for measuring the ion flow through transmembrane protein hole are known in the art and disclosed in the embodiment.Described method is usually carried out by the voltage applied on described film and described hole.The voltage used is usually from +5V to -5V, for example from from +4V to -4V, from +3V to -3V or from +2V to -2V.The voltage used is usually from -600mV to +600V or -400mV to +400mV. The voltage used is preferably in a range having a lower limit selected from -400mV, -300mV, -200mV, -150mV, -100mV, -50mV, -20mV and 0mV and an upper limit independently selected from +10mV, +20mV, +50mV, +100mV, +150mV, +200mV, +300nV and +400mV. The voltage used is more preferably in the range of 100mV to 240mV and most preferably in the range of 120mV to 220mV. By using an increased applied potential, the recognition of different nucleotides by the hole can be increased.

[0122] The method is generally carried out in the presence of any charge carrier, such as a metal salt such as an alkali metal salt, a halide salt such as a chloride salt, such as an alkali metal chloride salt. The charge carrier may include an ionic liquid or an organic salt, such as tetramethylammonium chloride, trimethylphenylammonium chloride, phenyltrimethylammonium chloride or 1-ethyl-3-methylimidazolium chloride. In the exemplary device described above, the salt is present in an aqueous solution in the chamber. Potassium chloride (KCl), sodium chloride (NaCl), cesium chloride (CsCl) or a mixture of potassium ferrocyanide and potassium ferrocyanide are generally used. A mixture of KCl, NaCl and potassium ferrocyanide and potassium ferrocyanide is preferred. The charge carrier may be asymmetric on the membrane. For example, the type and / or concentration of the charge carrier may be different on each side of the membrane.

[0123] The concentration of the salt may be saturated. The concentration of the salt may be 3 M or less, and is typically 0.1 to 2.5 M, 0.3 to 1.9 M, 0.5 to 1.8 M, 0.7 to 1.7 M, 0.9 to 1.6 M or 1 M to 1.4 M. The concentration of the salt is preferably 150 mM to 1 M. The method is preferably performed using a salt concentration of at least 0.3 M, such as at least 0.4 M, at least 0.5 M, at least 0.6 M, at least 0.8 M, at least 1.0 M, at least 1.5 M, at least 2.0 M, at least 2.5 M or at least 3.0 M. High salt concentrations provide a high signal-to-noise ratio and allow the presence of nucleotides to be identified in the context of normal current fluctuations to be indicated by current.

[0124] The method is typically carried out in the presence of a buffer. In the exemplary device described above, the buffer is present in an aqueous solution in the chamber. Any buffer can be used for the method of the present invention. Typically, the buffer is a phosphate buffer. Other suitable buffers are HEPES or Tris-HCl buffer. The method is typically carried out at a pH of 4.0 to 12.0, 4.5 to 10.0, 5.0 to 9.0, 5.5 to 8.8, 6.0 to 8.7, 7.0 to 8.8, or 7.5 to 8.5. The pH used is preferably about 7.5.

[0125] The method can be carried out at a temperature of 0°C to 100°C, 15°C to 95°C, 16°C to 90°C, 17°C to 85°C, 18°C ​​to 80°C, 19°C to 70°C or 20°C to 60°C. The method is usually carried out at room temperature. The method is optionally carried out at a temperature that supports the function of the enzyme and the system in which it is located, such as about 37°C or about 38°C.

[0126] In a preferred embodiment, the method comprises:

[0127] (a) contacting the target analyte with a nanopore and a helicase mutant of the invention, such that the helicase mutant controls movement of the target analyte through the pore;

[0128] (b) applying an electric potential across the pore to cause the target analyte to migrate through the pore; and

[0129] (c) obtaining one or more characteristics of the target analyte when interacting with the pore to obtain the presence, absence or one or more characteristics of the target analyte.

[0130] The above-mentioned prior art is incorporated herein by reference in its entirety.

[0131] The following examples are provided to illustrate the present invention but are not intended to limit the present invention.

[0132] Example

[0133] Example 1. Expression and purification of helicase mutants and corresponding helicases without rigidification of flexible regions in Escherichia coli

[0134] In an embodiment, the corresponding helicase M2 without rigidification of the flexible region is a Pif1-like helicase shown in SEQ ID NO: 1, and the Pif1-like helicase is derived from the Edwardsiella phage PEi26 Pif1-like helicase (Uniprot ID: A0A0B6VP37), and includes M1G / D99C / V155I / F246Y / E286K / S293N / C308T / A366C / C419D site mutations on the basis of the sequence shown in SEQ ID NO: 6 disclosed in WO2021253410A1, and the two sites with higher B factors in its amino acid sequence are shown in Table 2.

[0135] Table 2 Two amino acid sites with higher B factors in M2

[0136]

[0137] By site-directed mutagenesis of the Loop region and the amino acid positions with higher B factors, plasmids encoding the helicase mutants shown in Table 3 were obtained.

[0138] Table 3 Helicase mutants with rigid flexible regions

[0139]

[0140] The synthesized mutant gene plasmid was heat-shock transformed into the competent cells of Escherichia coli BL21 (DE3) Plys to obtain the recombinant strain. The monoclonal colonies on the plate were picked for strain preservation. The revived seeds were cultured for seed expansion. After IPTG induced protein expression for 20 hours, the bacteria were collected. The obtained bacteria were broken by homogenizer, the supernatant was taken, and the expression of the target protein was detected by WB. The mutants that were detected were purified by protein to obtain the recombinant enzyme ( Figure 1a ).

[0141] Example 2. Analysis of helicase activity of helicase mutants and corresponding helicases without rigidification of flexible regions

[0142] The helicase mutant and the corresponding helicase without rigidification of the flexible region were reacted with a fluorescent substrate, which had a 5' ssDNA protrusion, a 50-base hybridized dsDNA part, and a 3' end with a fluorescent group and a quenching group on each chain. As the helicase moves from the 5' end to the 3' end, the fluorescent group is released when the double helix is ​​unwound, thereby increasing the detected fluorescent signal. The amplitude of the increase in the fluorescent signal reflects the level of helicase activity. After the fluorescent substrate is incubated with the enzyme and cross-linked, ATP / Mg is added to 2+ The changes in fluorescence signals were recorded at the same time to obtain the relative helicase activity of the mutant relative to the M2 control. It was found that the helicase activity of the mutant was not much different from that of the M2 control, ranging from 0.5 to 1.1 times that of the control ( Figure 1c ).

[0143] Example 3. Analysis of ATPase activity of helicase mutants and corresponding helicases without rigidification of flexible regions

[0144] The helicase was cross-linked to the single-stranded DNA substrate, and the complex was incubated in a sequencing environment for 2 hours. The amount of ATP consumed and ADP produced by the rate-controlling enzyme was detected by HPLC, thereby reflecting the relative ATPase activity of the mutant, such as Figure 1d As shown, the ATPase activity of most of the helicase mutants did not change much at 34°C, ranging from 0.46 to 1.00 times that of the control. For the combined mutations of S32 and S33, the Tm value was high (see Figure 1b ), although the ATPase activity is more than half of that of M2, and the sequencing speed is slower than that of M2, it can obtain more reads and higher throughput than M2 (see Figure 2a-2c ).

[0145] Example 4. Analysis of ssDNA substrate binding ability of helicase mutants and corresponding helicases without rigidification of flexible regions

[0146] The helicase mutant and M2 control were cross-linked with fluorescently labeled T44, and incubated at 34°C for 0 or 1 hour under high salt conditions. The affinity of single-stranded DNA to the rate-controlling enzyme and its mutants was detected by TBE non-denaturing gel electrophoresis. It was found that at 0h, the migration rate of the fluorescent substrate added to the enzyme slowed down relative to the T44 substrate, and the migration slowdown was not much different between different mutants (such as Figure 1e As shown in the figure above). After heating in high salt for 1 hour, the mutants of the present invention improved the affinity between the substrate and the enzyme to varying degrees (such as Figure 1e (As shown in the figure below). Compared with M2, except for S03 / S04 / S21, which had a slight improvement in the affinity of the substrate, the affinity of all other mutants to the substrate was significantly improved.

[0147] Example 5. Thermal stability analysis of helicase mutants and corresponding helicases without rigidification of flexible regions

[0148] The basic principle of the enzyme thermal stability detection method is to use the fact that proteins will unfold during continuous heating, thereby exposing the hydrophobic core area, and the hydrophobic fluorescent dye will fluoresce after binding to the hydrophobic area. As more and more proteins unfold, the fluorescence will gradually increase, reaching a peak after a certain extent, and then gradually weaken as the unfolded proteins aggregate, forming an inverted U curve. The operation method is to mix the protein, buffer and protein fluorescent dye, and run a melting curve experiment on a Bio-Rad CFX96 real-time quantitative PCR instrument or other suitable qPCR instrument. As the protein unfolds due to heat, the fluorescent dye binds to the exposed hydrophobic area and emits fluorescence. The rate of change is determined by plotting a negative-one regression graph of relative fluorescence against temperature, resulting in a visible peak, which represents the melting temperature (Tm) of the protein in the corresponding buffer. We cross-linked the helicase with the substrate and detected the thermal stability of the helicase after forming a complex with the substrate ( Figure 1b ), it was found that the Tm value of the helicase mutant of the present invention was increased relative to that of the control M2.

[0149] Example 6 Application of helicase mutants and corresponding helicases without rigidification of flexible regions in nanopore sequencing

[0150] The helicase mutant and the corresponding helicase without rigid flexible region were separately constructed and mixed for 24 hours at 38°C with the same input amount on the Qnome-3841 sequencer. According to the instructions of the Qnome-3841 sequencer manual, the sequencing speed, relative read count and relative flux were analyzed, and it was found that the sequencing speed of the mutant with rigid flexible region was slightly reduced at high temperature compared with the corresponding helicase without rigid flexible region ( Figure 2c ), but the number of sequencing reads increased significantly within the same sequencing time ( Figure 2a ), and the relative flux also increased significantly ( Figure 2b ), from the temporal distribution of sequencing reads, the mutants with rigid flexible regions prolonged the sequencing time ( Figure 2d ).

[0151] Example 7: Other directions of rigidification of the flexible zone

[0152] First, for the G158, S159, G161, A432 and G435 sites mutated in Example 1, other mutation directions can also be selected. For example, for the G158 site, the optional amino acid modification includes deletion or replacement with P / N / Q; for the S159 site, the optional amino acid modification includes deletion or replacement with D / E / A / T / Y / N / Q; for the G161 site, the optional amino acid modification includes deletion or replacement with E / Q / T / I / V / L / S / M / N / Y; for the A432 site, in addition to mutation to L, mutation to other amino acids with larger side chains or stronger rigidity, the optional amino acid modification includes replacement with L / V / I / T / S / M / Y / N / Q / P / W / F; for the G435 site, the optional amino acid modification includes replacement with A / S / L / V / I / T / M / Y / N / Q / P / W / F.

[0153] Similarly, the corresponding amino acid sites of G158, S159, G161, A432 and G435 in other helicases (see Table 3) can also be rigidified in the flexible regions to improve sequencing performance. The optional amino acid modifications for flexible region mutations are summarized in the last row of Table 4.

[0154] Table 4 Corresponding amino acid positions of G158, S159, G161, A432 and G435 in other helicases

[0155]

[0156]

[0157] In addition, the regions that can be rigidified in the flexible region are not limited to the corresponding amino acid sites of G158, S159, G161, A432 and G435, but can also be amino acid sequences showing a secondary structure of a loop in the helicase structure. The corresponding positions in homologous proteins are shown in Table 5 below.

[0158] Table 5 Loop region in helicase

[0159]

[0160]

Claims

1. A helicase mutant whose flexible region is rigidified and retains the ability to control the movement of a polynucleotide through a nanopore.

2. The helicase mutant according to claim 1, wherein the helicase mutant has improved sequencing performance compared to the corresponding helicase without rigidification of the flexible region, such as reduced sequencing speed, increased number of sequencing reads within the same sequencing time (or increased pore frequency), increased sequencing throughput and / or extended sequencing time.

3. The helicase mutant according to claim 1 or 2, wherein the flexible region is rigidified by one or more amino acid modifications at the Loop region and / or amino acid residues with higher B factors.

4. The helicase mutant according to any one of claims 1 to 3, wherein the corresponding helicase that has not been rigidified by the flexible region is a helicase of helicase superfamily 1 or superfamily 2 or a functional variant thereof, preferably a Pif1-like helicase, Upf1-like helicase, UvrD / Rep helicase, Ski-like helicase, Rad3 / XPD helicase, NS3 / NPH-II helicase, DEAD helicase, DEAH / RHA helicase, RecG-like helicase, REcQ-like helicase, T1R-like helicase, Swi / Snf-like helicase or Rig-I-like helicase or a functional variant thereof, more preferably a Pif1-like helicase or a functional variant thereof.

5. The helicase mutant according to any one of claims 1 to 4, wherein the corresponding helicase that has not been rigidified by the flexible region comprises the amino acid sequence shown in SEQ ID NO: 1 or comprises an amino acid sequence that is at least 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, 99.5% identical to the amino acid sequence shown in SEQ ID NO: 1, and the helicase mutant has one or more amino acid modifications at the following sites corresponding to SEQ ID NO: 1: G158, S159, G161, A432 and G435, preferably the helicase mutant has one or more of the following amino acid modifications: ΔG158 / ΔS159, ΔG161, A432L, G435A.

6. A polynucleotide encoding the helicase mutant according to any one of the preceding claims. A vector comprising the polynucleotide according to claim 6. A host cell comprising the vector according to claim 7.

9. A method for preparing a helicase mutant according to any one of claims 1 to 5, comprising expressing a nucleic acid according to claim 6, transfecting a cell with an expression vector according to claim 7, or culturing a host cell according to claim 8.

10. A construct comprising the helicase mutant described in any one of claims 1 to 5 or the helicase mutant prepared by the method of claim 9, and a loading portion bound to the helicase mutant. Optionally, the construct further comprises a target analyte, which is located in a preset moving direction of the helicase mutant.

11. A product comprising the helicase mutant according to any one of claims 1 to 5, the nucleic acid according to claim 6, the vector according to claim 7, the host cell according to claim 8, the helicase mutant prepared by the method according to claim 9 or the construct according to claim 10, and a pore, wherein the product is used to determine the presence, absence or one or more characteristics of a target analyte; Optionally, the product is selected from a kit, a device or a sensor.

12. A method for determining the presence, absence, or one or more characteristics of a target analyte, the method comprising: (a) contacting the target analyte with a nanopore and a helicase mutant according to any one of claims 1 to 5 or a helicase mutant prepared by the method of claim 9, such that the helicase mutant controls the movement of the target analyte through the pore; (b) applying an electric potential across the pore to cause the target analyte to migrate through the pore; as well as (c) obtaining one or more characteristics of the target analyte when interacting with the pore to obtain the presence, absence or one or more characteristics of the target analyte.

13. The product according to claim 11 or the method according to claim 12, wherein the target analyte is selected from one or more of polynucleotides, polypeptides, polysaccharides and lipids, preferably polynucleotides or polypeptides, polysaccharides and lipids linked to polynucleotides, more preferably single-stranded polynucleotides, double-stranded polynucleotides or partially double-stranded polynucleotides; wherein the one or more characteristics are selected from the group consisting of length, identity, specific sequence, secondary structure, and modification (methylation, oxidation, damage, marker, tag, or spacer modification) of the target analyte; The pore is selected from a biological pore, a solid-state pore or a hybrid biological and solid-state pore.

14. The helicase mutant according to any one of claims 1 to 5, the nucleic acid according to claim 6, the vector according to claim 7, the host cell according to claim 8, the helicase mutant prepared by the method according to claim 9, the construct according to claim 10, the product according to claim 11, or the use of the method according to any one of claims 12-13 in preparing a product for characterizing a target analyte or in characterizing a target analyte.